Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 10/2017

27.05.2017 | Original Article – Clinical Oncology

Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation

verfasst von: Christoph Busemann, Andreas Jülich, Britta Buchhold, Vanessa Schmidt, Laila Schneidewind, Daniel Pink, Christian Andreas Schmidt, Thomas Neumann, William H. Krüger

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Allogeneic stem cell transplantation may cure approximately 50% of patients, however, a significant part of the other half might benefit from a high-quality palliative care medicine at the end of life. Somatic, psychic and spiritual needs of these patients may differ from those of patients suffering from incurable solid tumours and are not comprehensively evaluated so far.

Methods

To address this question, data from charts of 123 patients who have died after allogeneic stem cell transplantation were extracted. In detail, the time line of the clinical course, the symptoms, the administered drugs and other applied procedures were analysed.

Results

Approximately one half of the patients, who have died after stem cell transplantation, did not live more than 5 months. Two-thirds of patients died within 14 months after SCT. 28.5% of the patients could not be discharged after transplantation. However, a significant proportion had a low ECOG-score (0–1) prior to death, indicating a high degree of mobility. Major symptoms were weakness, fatigue and need for aid at daily activities. Severe pain, dyspnoea and obstipation, as known from patients suffering from advanced solid tumours, were rare. In consequence, use of opioids seemed to be less frequent than in patients with solid tumours. Measures of intensive care and i.v.-drug administration were applied to a significant proportion of patients.

Conclusion

The present investigation indicates that the somatic, psychic and spiritual end-of-life-care after allogeneic stem cell transplantation could be optimised. A significant problem for the transplantation team seems to be the realisation of necessity to switch the curative concept into a palliative ambition. Requirements are a subsequent prospectively conducted investigation and an intensification of cooperation between transplant and palliative care teams.
Literatur
Zurück zum Zitat Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15(12):1628–1633CrossRefPubMedPubMedCentral Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15(12):1628–1633CrossRefPubMedPubMedCentral
Zurück zum Zitat Bearman SI, Appelbaum FR, Back A, Petersen FB, Buckner CD, Sullivan KM et al (1989) Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 7(9):1288–1294CrossRefPubMed Bearman SI, Appelbaum FR, Back A, Petersen FB, Buckner CD, Sullivan KM et al (1989) Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 7(9):1288–1294CrossRefPubMed
Zurück zum Zitat Blume KG, Forman SJ, Appelbaum FR (eds) (2004) Thomas’ hematopoietic cell transplantation, 3rd edn. Blackwell Publishing, Malden MA Blume KG, Forman SJ, Appelbaum FR (eds) (2004) Thomas’ hematopoietic cell transplantation, 3rd edn. Blackwell Publishing, Malden MA
Zurück zum Zitat Busemann C, Ribback S, Zimmermann K, Sailer V, Kiefer T, Schmidt CA et al (2012) Toxoplasmosis after allogeneic stem cell transplantation—a single centre experience. Ann Hematol 91(7):1081–1089CrossRefPubMed Busemann C, Ribback S, Zimmermann K, Sailer V, Kiefer T, Schmidt CA et al (2012) Toxoplasmosis after allogeneic stem cell transplantation—a single centre experience. Ann Hematol 91(7):1081–1089CrossRefPubMed
Zurück zum Zitat Chung HM, Lyckholm LJ, Smith TJ (2009) Palliative care in BMT. Bone Marrow Transplant 43(4):265–273CrossRefPubMed Chung HM, Lyckholm LJ, Smith TJ (2009) Palliative care in BMT. Bone Marrow Transplant 43(4):265–273CrossRefPubMed
Zurück zum Zitat Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10(9):855–864CrossRefPubMed Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al (2009) Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10(9):855–864CrossRefPubMed
Zurück zum Zitat Gagnon B, Scott S, Nadeau L, Lawlor PG (2015) Patterns of community-based opioid prescriptions in people dying of cancer. J Pain Symptom Manag 49(1):36–44CrossRef Gagnon B, Scott S, Nadeau L, Lawlor PG (2015) Patterns of community-based opioid prescriptions in people dying of cancer. J Pain Symptom Manag 49(1):36–44CrossRef
Zurück zum Zitat Gencer D, Kastle-Larralde N, Pilz LR, Weiss A, Buchheidt D, Hochhaus A et al (2009) Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors. Onkologie 32(7):380–386CrossRefPubMed Gencer D, Kastle-Larralde N, Pilz LR, Weiss A, Buchheidt D, Hochhaus A et al (2009) Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors. Onkologie 32(7):380–386CrossRefPubMed
Zurück zum Zitat Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363(22):2091–2101CrossRefPubMedPubMedCentral Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363(22):2091–2101CrossRefPubMedPubMedCentral
Zurück zum Zitat Lafond DA, Kelly KP, Hinds PS, Sill A, Michael M (2015) Establishing feasibility of early palliative care consultation in pediatric hematopoietic stem cell transplantation. J Pediatr Oncol Nurs 32(5):265–277CrossRefPubMed Lafond DA, Kelly KP, Hinds PS, Sill A, Michael M (2015) Establishing feasibility of early palliative care consultation in pediatric hematopoietic stem cell transplantation. J Pediatr Oncol Nurs 32(5):265–277CrossRefPubMed
Zurück zum Zitat LeBlanc TW, O’Donnell JD, Crowley-Matoka M, Rabow MW, Smith CB, White DB et al (2015) Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study. J Oncol Pract 11(2):e230–e238CrossRefPubMedPubMedCentral LeBlanc TW, O’Donnell JD, Crowley-Matoka M, Rabow MW, Smith CB, White DB et al (2015) Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study. J Oncol Pract 11(2):e230–e238CrossRefPubMedPubMedCentral
Zurück zum Zitat Marr KA, Carter RA, Crippa F, Wald A, Corey L (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34(7):909–917CrossRefPubMed Marr KA, Carter RA, Crippa F, Wald A, Corey L (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34(7):909–917CrossRefPubMed
Zurück zum Zitat Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347(25):2020–2029CrossRefPubMed Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347(25):2020–2029CrossRefPubMed
Zurück zum Zitat Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101(4):1620–1629CrossRefPubMed Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101(4):1620–1629CrossRefPubMed
Zurück zum Zitat Polanski J, Jankowska-Polanska B, Rosinczuk J, Chabowski M, Szymanska-Chabowska A (2016) Quality of life of patients with lung cancer. Onco Targets Ther 29(9):1023–1028. doi:10.2147/OTT.S100685 (eCollection 2016) Polanski J, Jankowska-Polanska B, Rosinczuk J, Chabowski M, Szymanska-Chabowska A (2016) Quality of life of patients with lung cancer. Onco Targets Ther 29(9):1023–1028. doi:10.​2147/​OTT.​S100685 (eCollection 2016)
Zurück zum Zitat Radbruch L, Sabatowski R, Loick G, Jonen-Thielemann I, Kasper M, Gondek B et al (2000) Cognitive impairment and its influence on pain and symptom assessment in a palliative care unit: development of a minimal documentation system. Palliat Med 14(4):266–276CrossRefPubMed Radbruch L, Sabatowski R, Loick G, Jonen-Thielemann I, Kasper M, Gondek B et al (2000) Cognitive impairment and its influence on pain and symptom assessment in a palliative care unit: development of a minimal documentation system. Palliat Med 14(4):266–276CrossRefPubMed
Zurück zum Zitat Roeland E, Mitchell W, Elia G, Thornberry K, Herman H, Cain J et al (2010) Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 2: psychosocial concerns. J Support Oncol 8(4):179–183PubMed Roeland E, Mitchell W, Elia G, Thornberry K, Herman H, Cain J et al (2010) Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 2: psychosocial concerns. J Support Oncol 8(4):179–183PubMed
Zurück zum Zitat Schmidt-Wolf G, Elsner F, Lindena G, Hilgers RD, Heussen N, Rolke R et al (2013) Evaluation of 12 pilot projects to improve outpatient palliative care. Dtsch Med Wochenschr 138(50):2585–2591CrossRefPubMed Schmidt-Wolf G, Elsner F, Lindena G, Hilgers RD, Heussen N, Rolke R et al (2013) Evaluation of 12 pilot projects to improve outpatient palliative care. Dtsch Med Wochenschr 138(50):2585–2591CrossRefPubMed
Zurück zum Zitat Sievers CK, Kratz JD, Zurbriggen LD, LoConte NK, Lubner SJ, Uboha N et al (2016) The multidisciplinary management of colorectal cancer: present and future paradigms. Clin Colon Rectal Surg 29(3):232–238CrossRefPubMedPubMedCentral Sievers CK, Kratz JD, Zurbriggen LD, LoConte NK, Lubner SJ, Uboha N et al (2016) The multidisciplinary management of colorectal cancer: present and future paradigms. Clin Colon Rectal Surg 29(3):232–238CrossRefPubMedPubMedCentral
Zurück zum Zitat Sorror M (2009) Impacts of pretransplant comorbidities on allogeneic hematopoietic cell transplantation (HCT) outcomes. Biol Blood Marrow Transplant 15(1 Suppl):149–153CrossRefPubMed Sorror M (2009) Impacts of pretransplant comorbidities on allogeneic hematopoietic cell transplantation (HCT) outcomes. Biol Blood Marrow Transplant 15(1 Suppl):149–153CrossRefPubMed
Zurück zum Zitat Späth C, Busemann C, Krüger WH (2014) Allogeneic stem cell transplantation in patients above 55: suggestion for a further stratification of the HCT-CI. J Cancer Res Clin Oncol 140(11):1981–1988CrossRefPubMed Späth C, Busemann C, Krüger WH (2014) Allogeneic stem cell transplantation in patients above 55: suggestion for a further stratification of the HCT-CI. J Cancer Res Clin Oncol 140(11):1981–1988CrossRefPubMed
Zurück zum Zitat Stiel S, Psych D, Kues K, Krumm N, Radbruch L, Elsner F (2011) Assessment of quality of life in patients receiving palliative care: comparison of measurement tools and single item on subjective well-being. J Palliat Med 14(5):599–606CrossRefPubMed Stiel S, Psych D, Kues K, Krumm N, Radbruch L, Elsner F (2011) Assessment of quality of life in patients receiving palliative care: comparison of measurement tools and single item on subjective well-being. J Palliat Med 14(5):599–606CrossRefPubMed
Zurück zum Zitat Van CE, Sagaert X, Topal B, Haustermans K, Prenen H (2016) Gastric cancer. Lancet 16:10–6736CrossRef Van CE, Sagaert X, Topal B, Haustermans K, Prenen H (2016) Gastric cancer. Lancet 16:10–6736CrossRef
Zurück zum Zitat Yahav D, Gafter-Gvili A, Muchtar E, Skalsky K, Kariv G, Yeshurun M et al (2009) Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer 45(18):3131–3148CrossRefPubMed Yahav D, Gafter-Gvili A, Muchtar E, Skalsky K, Kariv G, Yeshurun M et al (2009) Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur J Cancer 45(18):3131–3148CrossRefPubMed
Zurück zum Zitat Zeichner SB, Terawaki H, Gogineni K (2016) A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl) 22(10):25–36. doi:10.4137/BCBCR.S32783 (eCollection 2016) Zeichner SB, Terawaki H, Gogineni K (2016) A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl) 22(10):25–36. doi:10.​4137/​BCBCR.​S32783 (eCollection 2016)
Metadaten
Titel
Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation
verfasst von
Christoph Busemann
Andreas Jülich
Britta Buchhold
Vanessa Schmidt
Laila Schneidewind
Daniel Pink
Christian Andreas Schmidt
Thomas Neumann
William H. Krüger
Publikationsdatum
27.05.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2446-y

Weitere Artikel der Ausgabe 10/2017

Journal of Cancer Research and Clinical Oncology 10/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.